SEC Form 4 · accession 0000874015-16-000145

IONIS PHARMACEUTICALS INC · IONS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Finance & CFO

Period of report

Nov 9, 2016

Accepted (ET)

Nov 14, 2016 · 6:52 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000874015

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Nov 9, 2016	M	2,500	$11.27	A	9,048	D
Common Stock^F1,F2	Nov 9, 2016	S	2,500	$38.49	D	6,548	D
Common Stock^F1	Nov 11, 2016	M	2,500	$11.27	A	9,048	D
Common Stock^F1	Nov 11, 2016	S	2,500	$41.00	D	6,548	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)	$11.27	Nov 9, 2016	M	2,500	D	Jan 4, 2014	Jan 3, 2017	Common Stock	2,500	7,500	D
Employee Stock Option (right to buy)	$11.27	Nov 11, 2016	M	2,500	D	Jan 4, 2014	Jan 3, 2017	Common Stock	2,500	5,000	D

F1Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.56, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.